MA26427A1 - Trihydrate de mesylate de 5-(2-(4-(1,2-benzisothiazole-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indole-2-one, procede pour sa preparation et compositions pharmaceutiques le contenant - Google Patents

Trihydrate de mesylate de 5-(2-(4-(1,2-benzisothiazole-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indole-2-one, procede pour sa preparation et compositions pharmaceutiques le contenant

Info

Publication number
MA26427A1
MA26427A1 MA24594A MA24594A MA26427A1 MA 26427 A1 MA26427 A1 MA 26427A1 MA 24594 A MA24594 A MA 24594A MA 24594 A MA24594 A MA 24594A MA 26427 A1 MA26427 A1 MA 26427A1
Authority
MA
Morocco
Prior art keywords
benzisothiazole
piperazinyl
indole
dihydro
chloro
Prior art date
Application number
MA24594A
Other languages
English (en)
Inventor
A Rose Carol
R Busch Frank
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA26427A1 publication Critical patent/MA26427A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA24594A 1996-05-07 1997-05-06 Trihydrate de mesylate de 5-(2-(4-(1,2-benzisothiazole-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indole-2-one, procede pour sa preparation et compositions pharmaceutiques le contenant MA26427A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1653796P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
MA26427A1 true MA26427A1 (fr) 2004-12-20

Family

ID=21777622

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24594A MA26427A1 (fr) 1996-05-07 1997-05-06 Trihydrate de mesylate de 5-(2-(4-(1,2-benzisothiazole-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indole-2-one, procede pour sa preparation et compositions pharmaceutiques le contenant

Country Status (45)

Country Link
US (1) US6110918A (fr)
EP (1) EP0904273B1 (fr)
JP (1) JP3102896B2 (fr)
KR (1) KR100333214B1 (fr)
CN (1) CN1092658C (fr)
AP (1) AP838A (fr)
AR (1) AR007003A1 (fr)
AT (1) ATE236902T1 (fr)
AU (1) AU730856C (fr)
BG (1) BG63601B1 (fr)
BR (1) BR9708932A (fr)
CA (1) CA2252895C (fr)
CO (1) CO4940465A1 (fr)
CZ (1) CZ289216B6 (fr)
DE (1) DE69720719T2 (fr)
DK (1) DK0904273T3 (fr)
DZ (1) DZ2221A1 (fr)
EA (1) EA001180B1 (fr)
EG (1) EG24401A (fr)
ES (1) ES2192264T3 (fr)
GT (1) GT199700042A (fr)
HN (1) HN1997000040A (fr)
HR (1) HRP970235B1 (fr)
HU (1) HU229057B1 (fr)
ID (1) ID17504A (fr)
IL (1) IL126590A (fr)
IS (1) IS2301B (fr)
MA (1) MA26427A1 (fr)
ME (1) ME00901B (fr)
MY (1) MY128051A (fr)
NO (1) NO312513B1 (fr)
NZ (2) NZ508303A (fr)
OA (1) OA10908A (fr)
PL (1) PL188164B1 (fr)
PT (1) PT904273E (fr)
SI (1) SI0904273T1 (fr)
SK (1) SK282674B6 (fr)
TN (1) TNSN97073A1 (fr)
TR (1) TR199802241T2 (fr)
TW (1) TW427989B (fr)
UA (1) UA47467C2 (fr)
UY (1) UY24543A1 (fr)
WO (1) WO1997042190A1 (fr)
YU (1) YU49398B (fr)
ZA (1) ZA973875B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
DE69910706T2 (de) * 1998-05-26 2004-07-08 Pfizer Products Inc., Groton Medikament zur Behandlung von Glaukoma und ischämischer Retinopathie
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
YU43702A (sh) 1999-12-23 2004-11-25 Pfizer Products Inc. Farmaceutske kompozicije koje obezbeđuju povećanje koncentracije leka
KR20030007824A (ko) * 2000-06-02 2003-01-23 화이자 프로덕츠 인크. 정신의학적 장애 및 안질환의 치료를 위한s-메틸-디히드로-지프라시돈
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
US7488729B2 (en) 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
WO2004050655A1 (fr) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Formes polymorphes de ziprasidone et son chlorhydrate
JP2007502856A (ja) * 2003-05-16 2007-02-15 ファイザー・プロダクツ・インク 精神病性障害および抑うつ性障害の治療
BRPI0410419A (pt) * 2003-05-16 2006-05-30 Pfizer Prod Inc tratamento para a ansiedade com ziprasidona
EP1626722A1 (fr) * 2003-05-16 2006-02-22 Pfizer Products Inc. Procede pour ameliorer les fonctions cognitives en administrant du ziprasidone
US7678799B2 (en) * 2003-06-03 2010-03-16 Teva Pharmaceutical Industries Ltd. Crystalline ziprasidone HCl and processes for preparation thereof
KR20060115350A (ko) * 2003-09-02 2006-11-08 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
CA2543805A1 (fr) * 2003-10-24 2005-05-06 Gideon Pilarsky Procedes de preparation de ziprasidone
JP2007514001A (ja) * 2003-12-18 2007-05-31 テバ ファーマシューティカル インダストリーズ リミティド ジプラシドン塩基の多形形態b2
EP1703898A2 (fr) * 2003-12-31 2006-09-27 Alpharma, Inc. Formulations de ziprasidone
ATE451367T1 (de) * 2004-02-27 2009-12-15 Ranbaxy Lab Ltd Verfahren zur herstellung von ziprasidon
US9044503B2 (en) * 2004-08-27 2015-06-02 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
EP2623095A1 (fr) * 2004-11-16 2013-08-07 Elan Pharma International Limited Formulations injectables de nanoparticules d'olanzapine
CA2593497A1 (fr) * 2005-02-11 2006-08-17 Judith Aronhime Ziprasidone mesylate amorphe
EP1855651A4 (fr) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd Compositions nanoparticulaires de derives d'amide heterocyclique
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
EP1858892A1 (fr) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Mesylate de ziprasidone anhydre et son procede de preparation
EP1858891A2 (fr) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Formes cristallines de mesylate de ziprasidone
AU2008254957A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
KR100948126B1 (ko) * 2007-12-10 2010-03-18 씨제이제일제당 (주) 결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물
CN102234273B (zh) * 2010-04-21 2015-08-05 上海医药工业研究院 甲磺酸齐拉西酮半水合物及其制备方法
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one

Also Published As

Publication number Publication date
EG24401A (en) 2009-04-29
PT904273E (pt) 2003-06-30
OA10908A (en) 2001-10-26
HRP970235B1 (en) 2002-08-31
CN1092658C (zh) 2002-10-16
NO985193L (no) 1998-11-06
PL188164B1 (pl) 2004-12-31
JP3102896B2 (ja) 2000-10-23
IS2301B (is) 2007-10-15
BG63601B1 (bg) 2002-06-28
HK1017893A1 (en) 1999-12-03
SK282674B6 (sk) 2002-11-06
NZ332219A (en) 2005-02-25
EA001180B1 (ru) 2000-10-30
YU17397A (sh) 2000-10-30
DK0904273T3 (da) 2003-07-07
CZ289216B6 (cs) 2001-12-12
DZ2221A1 (fr) 2002-12-03
SK150598A3 (en) 2000-03-13
BR9708932A (pt) 1999-08-03
IS4878A (is) 1998-10-23
CZ349498A3 (cs) 1999-09-15
HUP9902808A2 (hu) 2000-03-28
CO4940465A1 (es) 2000-07-24
PL329880A1 (en) 1999-04-12
BG102893A (en) 1999-09-30
TR199802241T2 (fr) 1999-02-22
AP838A (en) 2000-05-03
HN1997000040A (es) 1997-06-05
KR100333214B1 (ko) 2002-06-20
IL126590A0 (en) 1999-08-17
IL126590A (en) 2001-11-25
US6110918A (en) 2000-08-29
DE69720719D1 (de) 2003-05-15
GT199700042A (es) 1998-10-02
EA199800909A1 (ru) 1999-04-29
ES2192264T3 (es) 2003-10-01
HUP9902808A3 (en) 2000-04-28
ATE236902T1 (de) 2003-04-15
ME00901B (me) 2005-11-28
AU730856B2 (en) 2001-03-15
YU49398B (sh) 2005-11-28
MY128051A (en) 2007-01-31
UA47467C2 (uk) 2002-07-15
TW427989B (en) 2001-04-01
UY24543A1 (es) 2000-09-29
EP0904273A1 (fr) 1999-03-31
EP0904273B1 (fr) 2003-04-09
CA2252895C (fr) 2002-08-20
JPH11509865A (ja) 1999-08-31
CA2252895A1 (fr) 1997-11-13
TNSN97073A1 (fr) 2005-03-15
SI0904273T1 (en) 2003-08-31
NO312513B1 (no) 2002-05-21
WO1997042190A1 (fr) 1997-11-13
NZ508303A (en) 2001-07-27
CN1216990A (zh) 1999-05-19
DE69720719T2 (de) 2003-11-06
ID17504A (id) 1998-01-08
HU229057B1 (en) 2013-07-29
HRP970235A2 (en) 1998-06-30
ZA973875B (en) 1998-11-06
AR007003A1 (es) 1999-10-13
KR20000010822A (ko) 2000-02-25
AP9700978A0 (en) 1997-07-31
AU1936897A (en) 1997-11-26
AU730856C (en) 2001-11-15
NO985193D0 (no) 1998-11-06

Similar Documents

Publication Publication Date Title
DZ2221A1 (fr) Trihydrate de mésylate de 5-(2-(4-(1,2-benzisothiazole-3-yi)-1-pipérazinyl)-éthyl)-6-chloro-1,3-dihydro-2h-indole-2-one, procédé pour sa préparation et compositions pharmaceutiques le contenant.
MA26430A1 (fr) 4 (3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26687A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
NO933093D0 (no) Monohydrat av 5-(2-(4-(1,2-benzisotiazol-3-yl)-1-piperazinyl)-etyl)-6-klor-1,3-dihydro-2h-indol-2-on hydroklorid
FR2780728B1 (fr) Sel de paroxetine nouveau, procede pour sa preparation et compositions pharmaceutiques le contenant
MA26598A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur préparation et compositions pharmaceutiques les contenant
MA26438A1 (fr) Derives 6,5-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26415A1 (fr) Composes heterocycliques, procede pour la preparation et compositions pharmaceutiques les contenant
MA26526A1 (fr) Derives d'indole inhibiteurs de cyclo-oxygenase, procede pour leur preparation et compositions pharmaceutiques les contenant.
RU93043528A (ru) Моногидрат 5-(2-(4-(1,2-бензотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2н-индол-2-он хлоргидрата, способ его получения, фармацевтическая композиция, способ лечения
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA23899A1 (fr) Procede pour la preparation de derives de pyrimidinedione et -trione, triazinedione et quinazolinedione, procede de preparation de compositions pharmaceutiques les contenant et leur utilisation
MA26559A1 (fr) Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
MA26472A1 (fr) Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
EP1045636A4 (fr) Compositions pharmaceutiques et procede d'utilisation de ces dernieres pour traiter des tissus myocardiques defaillants
MA26468A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26443A1 (fr) Aralkyl- et aralkylidene-lactames et -imides heterocycliques, procedes pour leur preparation et compositions pharmaceutiques les contenant
MA26519A1 (fr) Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26433A1 (fr) Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
BG102892A (en) Mesylate dihydrated salts of 5-(2-4(1,2-benzisothiazol-3-yl)-1-piperazinyl)-athyl)-6-chloro-1,3 -dihydro-2(1h)-indol-on(=ciprazidon), their preparation and application as dopamine d2 antagonists
MA26523A1 (fr) Modification thermodynamiquement stable de 1-(4-carbazolyloxy)-3-(2-(2-methoxyphenoxy) ethylamino)-2-propanole, procede pour sa preparation et compositions pharmaceutiques le comprenant
MA26417A1 (fr) Azetidines, procede pour leur preparation, et compositions pharmaceutiques les contenant
MA26582A1 (fr) Derives de thiazolidinedione nouveau, procede pour sa preparation et composition pharmaceutique le contenant
FR2728901B1 (fr) Derives de phenyl-4-thiazoles substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26609A1 (fr) Derives de retiferol, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation